Amphotericin B lipid complex is efficacious in the treatment of Candida albicans biofilms using a model of catheter-associated Candida biofilms

International Journal of Antimicrobial Agents

Volumn 33, Issue 2, 2009, Pages 149-153

  Mukherjee, Pranab K ^a   Long, Lisa ^a   Kim, Hyung Gun ^a   Ghannoum, Mahmoud A ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biofilms; Candida albicans; Polyenes; Rabbit model

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX;

ANIMAL EXPERIMENT; ARTICLE; BIOFILM; CANDIDA ALBICANS; CATHETER; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL RABBIT; FUNGAL CELL; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA ALBICANS; CATHETERS, INDWELLING; COLONY COUNT, MICROBIAL; MICROSCOPY, ELECTRON, SCANNING; MODELS, ANIMAL; RABBITS;

EID: 58149196359     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2008.07.030     Document Type: Article

References (34)

1. Rangel-Frausto M.S., Wiblin T., Blumberg H.M., Saiman L., Patterson J., Rinaldi M., et al. National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 29 (1999) 253-258
2. Edmond M.B., Wallace S.E., McClish D.K., Pfaller M.A., Jones R.N., and Wenzel R.P. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 29 (1999) 239-244
3. Fridkin S.K., and Jarvis W.R. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev 9 (1996) 499-511
4. Bertagnolio S., de Gaetano D.K., Tacconelli E., Scoppettuolo G., Posteraro B., Fadda G., et al. Hospital-acquired candidemia in HIV-infected patients. Incidence, risk factors and predictors of outcome. J Chemother 16 (2004) 172-178
5. Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P., and Edmond M.B. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39 (2004) 309-317
6. Gudlaugsson O., Gillespie S., Lee K., Vande Berg J., Hu J., Messer S., et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 37 (2003) 1172-1177
7. Diekema D.J., Beekmann S.E., Chapin K.C., Morel K.A., Munson E., and Doern G.V. Epidemiology and outcome of nosocomial and community-onset bloodstream infection. J Clin Microbiol 41 (2003) 3655-3660
8. DiGiovine B., Chenoweth C., Watts C., and Higgins M. The attributable mortality and costs of primary nosocomial bloodstream infections in the intensive care unit. Am J Respir Crit Care Med 160 (1999) 976-981
9. Nucci M., Colombo A.L., Silveira F., Richtmann R., Salomão R., Branchini M.L., et al. Risk factors for death in patients with candidemia. Infect Control Hosp Epidemiol 19 (1998) 846-850
10. O'Grady N.P., Alexander M., Dellinger E.P., Gerberding J.L., Heard S.O., Maki D.G., et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. MMWR Recomm Rep 51 (2002) 1-29
11. Mermel L.A., Farr B.M., Sherertz R.J., Raad I.I., O'Grady N., Harris J.S., et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 32 (2001) 1249-1272
12. Hawser S.P., and Douglas L.J. Biofilm formation by Candida species on the surface of catheter materials in vitro. Infect Immun 62 (1994) 915-921
13. Hawser S.P., and Douglas L.J. Resistance of Candida albicans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother 39 (1995) 2128-2131
14. Hawser S.P., Baillie G.S., and Douglas L.J. Production of extracellular matrix by Candida albicans biofilms. J Med Microbiol 47 (1998) 253-256
15. Baillie G.S., and Douglas L.J. Role of dimorphism in the development of Candida albicans biofilms. J Med Microbiol 48 (1999) 671-679
16. Chandra J., Mukherjee P.K., Leidich S.D., Faddoul F.F., Hoyer L.L., Douglas L.J., et al. Antifungal resistance of candidal biofilms formed on denture acrylic in vitro. J Dent Res 80 (2001) 903-908
17. Douglas L.J. Candida biofilms and their role in infection. Trends Microbiol 11 (2003) 30-36
18. Yeater K.M., Chandra J., Cheng G., Mukherjee P.K., Zhao X., Rodriguez-Zas S.L., et al. Temporal analysis of Candida albicans gene expression during biofilm development. Microbiology 153 (2007) 2373-2385
19. Green C.B., Cheng G., Chandra J., Mukherjee P., Ghannoum M.A., and Hoyer L.L. RT-PCR detection of Candida albicans ALS gene expression in the reconstituted human epithelium (RHE) model of oral candidiasis and in model biofilms. Microbiology 150 (2004) 267-275
20. Mukherjee P.K., Zhou G., Munyon R., and Ghannoum M.A. Candida biofilm: a well-designed protected environment. Med Mycol 43 (2005) 191-208
21. Chandra J., Kuhn D.M., Mukherjee P.K., Hoyer L.L., McCormick T., and Ghannoum M.A. Biofilm formation by the fungal pathogen Candida albicans-development, architecture and drug resistance. J Bacteriol 183 (2001) 5385-5394
22. Mukherjee P.K., Mohamed S., Chandra J., Kuhn D., Liu S., Antar O.S., et al. Alcohol dehydrogenase restricts the ability of the pathogen Candida albicans to form a biofilm on catheter surfaces through an ethanol-based mechanism. Infect Immun 74 (2006) 3804-3816
23. Mukherjee P.K., Chandra J., Kuhn D.M., and Ghannoum M.A. Mechanism of azole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols. Infect Immun 71 (2003) 4333-4340
24. Kuhn D.M., Chandra J., Mukherjee P.K., and Ghannoum M.A. Comparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces. Infect Immun 70 (2002) 878-888
25. Chandra J., McCormick T.S., Imamura Y., Mukherjee P.K., and Ghannoum M.A. Interaction of Candida albicans with adherent human peripheral blood mononuclear cells increases C. albicans biofilm formation and results in differential expression of pro- and anti-inflammatory cytokines. Infect Immun 75 (2007) 2612-2620
26. Kuhn D.M., Mukherjee P.K., Clarke T.A., Pujol C., Chandra J., Hajjeh R.A., et al. Candida parapsilosis characterization in an outbreak setting. Emerg Infect Dis 10 (2004) 1074-1081
27. Kuhn D.M., and Ghannoum M.A. Candida biofilms: antifungal resistance and emerging therapeutic options. Curr Opin Investig Drugs 5 (2004) 186-197
28. Chandra J., Patel J.D., Li J., Zhou G., Mukherjee P.K., McCormick T.S., et al. Modification of surface properties of biomaterials influences the ability of C. albicans to form biofilms. Appl Environ Microbiol 71 (2005) 8795-8801
29. Kuhn D.M., George T., Chandra J., Mukherjee P.K., and Ghannoum M.A. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 46 (2002) 1773-1780
30. Schinabeck M.K., Long L.A., Hossain M.A., Chandra J., Mukherjee P.K., Mohamed S., et al. Rabbit model of Candida albicans biofilm infection: liposomal amphotericin B antifungal lock therapy. Antimicrob Agents Chemother 48 (2004) 1727-1732
31. Shuford J.A., Rouse M.S., Piper K.E., Steckelberg J.M., and Patel R. Evaluation of caspofungin and amphotericin B deoxycholate against Candida albicans biofilms in an experimental intravascular catheter infection model. J Infect Dis 194 (2006) 710-713
32. Castagnola E., Marazzi M.G., Tacchella A., and Giacchino R. Broviac catheter-related candidemia. Pediatr Infect Dis J 24 (2005) 747
33. Viale P., Petrosillo N., Signorini L., Puoti M., and Carosi G. Should lock therapy always be avoided for central venous catheter-associated fungal bloodstream infections?. Clin Infect Dis 33 (2001) 1947-1948 Author reply: 1949-51
34. Johnson D.C., Johnson F.L., and Goldman S. Preliminary results treating persistent central venous catheter infections with the antibiotic lock technique in pediatric patients. Pediatr Infect Dis J 13 (1994) 930-931